Ani Pharmaceuticals (ANIP) Receivables - Net (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Receivables - Net data on file, last reported at $255.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 15.93% year-over-year to $255.4 million; the trailing twelve-month figure through Mar 2026 stood at $255.4 million (up 15.93% YoY), and the FY2025 full-year result was $281.1 million, up 26.77% from the prior year.
• Receivables - Net slipped to $255.4 million in Q1 2026, from $281.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $281.1 million in Q4 2025 to a low of $131.6 million in Q1 2022.
• A 5-year average of $192.2 million and a median of $174.7 million in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 62.35% in 2022 and slipped 3.95% in 2024, its largest moves.
• Tracing ANIP's Receivables - Net over 5 years: stood at $165.4 million in 2022, then fell by 2.03% to $162.1 million in 2023, then jumped by 36.8% to $221.7 million in 2024, then rose by 26.77% to $281.1 million in 2025, then fell by 9.13% to $255.4 million in 2026.
• Business Quant data shows ANIP's Receivables - Net at $255.4 million in Q1 2026, $281.1 million in Q4 2025, and $252.6 million in Q3 2025.